# Adlai Nortye Group Ltd. American (ANL) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $15.01, market value $967 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Adlai Nortye Group Ltd. American reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 193.3×**. Each dollar of revenue is priced at 193.3×, a level that requires very high margins or very fast growth to justify.
- **Free-cash-flow yield: -3.5%** (5-yr avg -36.3%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -714.0%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -710.6%**. The company reported a net loss over the last twelve months.
- **Return on equity: 426.9%**. A 426.9% return on equity is extremely high; check whether buybacks or debt have shrunk the equity base, which flatters the ratio.
- **Return on invested capital: -282.1%**. Return on all capital, debt included, is -282.1%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -103.2%**. Each dollar of assets produces -103.2% of profit.

## Growth
- **EPS growth (1 yr): -105.6%**. Earnings per share fell 105.6%.

## Financial health
- **Net debt / EBITDA: net cash**. Adlai Nortye Group Ltd. American holds more cash than debt.
- **Interest coverage: -24.0×**. Operating profit covers interest only -24.0×: fragile.
- **Current ratio: 0.65** (quick 0.65). Current liabilities exceed current assets, so the company depends on ongoing cash generation or refinancing to pay the next year's bills.
- **Altman Z-score: 9.44**. A Z-score of 9.44 places the company in the safe zone for bankruptcy risk.

## Dividends
- **Dividend: none**. Adlai Nortye Group Ltd. American does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (5 analysts). 5 analysts cover Adlai Nortye Group Ltd. American; the consensus is strong_buy, with an average price target of $28.60 (+91% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 752.8%** (YTD 957.0%, 3-mo 50.9%). The shares are up 752.8% over twelve months including dividends.
- **From 52-week high: -13.0%** (1607.6% above the low). Trading 13% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 61**. An RSI of 61 is neutral.
- **Beta (1 yr): 1.67** (volatility 151%). Beta of 1.67 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ANL · Page: https://foliofundamentals.com/stocks/anl

Not investment advice.